-
Daiichi Sankyo Appoints Ken Takeshita, MD as Global Head of R&D
Tokyo, Munich and Basking Ridge, NJ – February 22, 2021 – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced Ken Takeshita, MD will be named the new Global Head of Research & Development as of April 1, 2021. On that date, Dr. Junichi Koga will retire from the position,…
Daiichi Sankyo2021-02-22 13:14:52Daiichi Sankyo Appoints Ken Takeshita, MD as Global Head of R&D -
Daiichi Sankyo Creates New Business Unit to Unify Major Oncology Markets into One Streamlined Organization Dedicated to Patients with Cancer
Ken Keller Appointed as Head of the Oncology Business Unit Overseeing Global Oncology Strategy and U.S. and European Oncology Businesses
Daiichi Sankyo2020-11-11 20:09:14Daiichi Sankyo Creates New Business Unit to Unify Major Oncology Markets into One Streamlined Organization -
Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi Sankyo’s ADC DS-1062
• Agreement represents second collaboration between Daiichi Sankyo and AstraZeneca for a Daiichi Sankyo DXd antibody drug conjugate (ADC) • AstraZeneca to pay Daiichi Sankyo up to $6 billion in total consideration, including a $1 billion upfront payment and up to an additional $5 billion contingent…
Daiichi Sankyo2020-08-03 09:16:13Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi -
Daiichi Sankyo Files Declaratory Judgement Action Related to its Proprietary Antibody Drug Conjugate Technology
Tokyo, Japan, Munich, Germany, Basking Ridge, NJ (November 4 / 5, 2019): Daiichi Sankyo Co., Ltd announced today that the company has filed a Declaratory Judgement action in the District Court of Delaware in response to receiving communications from Seattle Genetics, Inc. with respect to a…
Daiichi Sankyo2019-12-12 16:00:02Daiichi Sankyo Files Declaratory Judgement Action Related to its Proprietary Antibody Drug Conjugate -
Daiichi Sankyo and AstraZeneca Announce Global Development and Commercialization Collaboration for Daiichi Sankyo’s HER2 Targeting Antibody Drug Conjugate [Fam-] Trastuzumab Deruxtecan (DS-8201)
• Collaboration combines Daiichi Sankyo’s scientific and technological excellence with AstraZeneca’s global experience and resources in oncology to accelerate and expand the potential of [fam-] trastuzumab deruxtecan as monotherapy and combination therapy across a spectrum of HER2 expressing cancers…
Daiichi Sankyo2019-05-28 13:30:01Daiichi Sankyo and AstraZeneca Announce Global Development and Commercialization Collaboration for Daiichi -
Daiichi Sankyo Shifts Several Top Leaders to New Roles for Company's Launch into its Next Growth Phase
- Dr. Junichi Koga to become new global Head of Research & Development Unit and Co-Chair of the company's Global Executive Meeting of R&D (GEMRAD), the top decision-making body in R&D - Ken Keller appointed President & CEO of Daiichi Sankyo, Inc., a U.S. affiliate - Dr. Glenn Gormley successfully…
Daiichi Sankyo2019-05-28 13:30:01Daiichi Sankyo Shifts Several Top Leaders to New Roles for Company's Launch into its Next Growth Phase -
Daiichi Sankyo Europe launches mycancertherapy.eu at ESMO 2018
New video-based website on cancer answers most frequently asked patient questions and simplifies medical jargon in 16 (EU & minority) different languages.
Daiichi Sankyo2018-11-22 13:00:01Daiichi Sankyo Europe launches mycancertherapy.eu at ESMO 2018 -
Daiichi Sankyo Announces 15 Billion Yen Manufacturing Investment to Support Acceleration of Antibody Drug Conjugate Portfolio
Intended for US and EU Medical Media Only - Significant investment in antibody drug conjugate (ADC) manufacturing capabilities will improve research productivity and accelerate clinical development of novel Daiichi Sankyo Cancer Enterprise ADC candidates including HER2-targeting DS-8201and…
Daiichi Sankyo2017-08-14 17:45:01Daiichi Sankyo Announces 15 Billion Yen Manufacturing Investment to Support Acceleration of Antibody Drug
